Solutex GC, S.L.   Report issue

For profit Phase 2
Founded: Madrid Spain (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2015
NCT02518672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Solutex (Spain)

Active Ingredients

Drugs in Phase 2 Trials (2)

fish oil (Omegavan) (1 trial)

icosapent ethyl (vascepa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2